Skip to main content
  • EN
  • FI
  • SV
Login

Main navigation

  • About FinnGen
    • Summary & Goals
      • Goals
      • FinnGen 1-2
      • FinnGen 3 (2023-2027)
    • Consortium
      • Partners
      • Funding
      • Governance
      • Steering Committee Members
      • Scientific Committee Members
      • Teams
      • Collaboration
    • Impact
      • National Impact
      • National Research Network
      • Open Science
      • Research Highlights
    • Why Finland?
      • Biobank Network
      • Legislative Review
      • National Registries
      • Population Genetic History
      • Industry partners
    • Mediabank
  • For Researchers
    • Research Activities
      • Core Analyses
      • Disease Task Forces
      • Expansion Areas
      • Global Initiatives
    • Cohort and Data
      • Register Data
      • Basic Characteristics
      • Clinical Endpoints
      • Genetic Data
      • Laboratory Values
      • Other Phenotype Data
      • Recruitment
      • Other Biological Data
      • Data Available
    • Accessing Data, Results & Tools
      • Access results
      • Computing environment
      • How we collaborate
      • Partner researchers
      • Public data releases
      • Tools
    • Publications
    • Researcher FAQ
  • For Participants
    • Participation
      • Study Participants
      • Biobanks' Role in FinnGen
      • Biobank Contact Information
      • Recall Studies
      • Questions and answers
    • Data Protection and Security
      • Data Protection
      • Data Security
      • Sample & Data Flow
      • Data Protection Statement
    • Significance
      • Videos
  • News
  • EN
  • FI
  • SV

Links

  • PheWeb
  • Risteys
  • Meta-analysis Pheweb (FG-MVP-UKBB)
  • FinnGen handbook
  • Meta-analysis Pheweb (FG-UKBB)
  • Coding variant browser
  • Endpoint Browser
  • FinnGen GITHUB
  • LAVAA volcano plot
  • Multiple Manhattan Plot
  • Variant Cluster Corrector
  • Variant Cluster Call Corrector
Breadcrumb
  1. Home

Machine Learning-Driven Identification and In Vitro Validation of the APOBEC3B-ANLN Regulatory Axis in Adrenocortical Carcinoma

Submitted by Anna Hakala on Tue, 02/03/2026 - 11:04
  • Read more about Machine Learning-Driven Identification and In Vitro Validation of the APOBEC3B-ANLN Regulatory Axis in Adrenocortical Carcinoma

Antihypertensive Drugs for the Prevention of Atrial Fibrillation: A Drug Target Mendelian Randomization Study

Submitted by Anna Hakala on Tue, 02/03/2026 - 11:03
  • Read more about Antihypertensive Drugs for the Prevention of Atrial Fibrillation: A Drug Target Mendelian Randomization Study

A large-scale multi-ancestry genome-wide association study of chronic prostatitis/chronic pelvic pain syndrome in men

Submitted by Anna Hakala on Tue, 02/03/2026 - 11:02
  • Read more about A large-scale multi-ancestry genome-wide association study of chronic prostatitis/chronic pelvic pain syndrome in men

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial

Submitted by Anna Hakala on Tue, 02/03/2026 - 10:53
  • Read more about An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial

The impact of anti-gout medications on eight cardiovascular diseases: a Mendelian randomized study

Submitted by Anna Hakala on Tue, 02/03/2026 - 10:51
  • Read more about The impact of anti-gout medications on eight cardiovascular diseases: a Mendelian randomized study

Genetic evidence supports therapeutic modulation of progranulin levels in Alzheimer’s Disease

Submitted by Anna Hakala on Tue, 02/03/2026 - 10:50
  • Read more about Genetic evidence supports therapeutic modulation of progranulin levels in Alzheimer’s Disease

Oncostatin M mediates the causal relationship between obesity and chronic kidney disease: evidence from Mendelian randomization and experimental validation

Submitted by Anna Hakala on Tue, 02/03/2026 - 10:49
  • Read more about Oncostatin M mediates the causal relationship between obesity and chronic kidney disease: evidence from Mendelian randomization and experimental validation

Multi-omics integrated analysis identifies causal risk factors and therapeutic targets for diabetic retinopathy

Submitted by Anna Hakala on Tue, 02/03/2026 - 10:48
  • Read more about Multi-omics integrated analysis identifies causal risk factors and therapeutic targets for diabetic retinopathy

1400 plasma metabolites and Sjögren’s syndrome: a Mendelian randomization analysis

Submitted by Anna Hakala on Tue, 02/03/2026 - 10:47
  • Read more about 1400 plasma metabolites and Sjögren’s syndrome: a Mendelian randomization analysis

Genetic insights into drug targets for alzheimer’s disease: integrative multi-omics analysis

Submitted by Anna Hakala on Tue, 02/03/2026 - 10:44
  • Read more about Genetic insights into drug targets for alzheimer’s disease: integrative multi-omics analysis

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Current page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Contact us

Contact person
finngen-info@helsinki.fi
Follow us on Bluesky
@finngen.bsky.social
Follow us on LinkedIn
https://www.linkedin.com/company/finngen/

Lead organisations

The University of Helsinki is the organization responsible for the FinnGen research project. The Finnish consortium partners include all Finnish public biobanks and their background organisations, so the project covers the whole of Finland. All partners are listed on this page.

About the website

Accessibility statement